drugset / Trial / NCT06394492
SHR-A1921 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
This study is a randomized, open-label, controlled, phase III study to evaluate the efficacy and safety of SHR-A1921 versus investigator's choice of chemotherapy in patients with platinum-resistant recurrent epithelial ovarian cancer.
Timeline
- Start
- 2024-05-10
- Primary completion
- 2026-05-31
- Completion
- 2026-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Doxorubicin | Other / unclassified | — | — |
| Comparator | Paclitaxel | Small molecule | — | — |
| Subject | SHR-A1921 | Monoclonal antibody | — | — |
| Comparator | Topotecan | Small molecule | — | — |